Understanding the ALTA-1L Trial
Watch
First-Line Treatment Options in ALK+ Lung Cancer
Molecular Testing in ALK+ Non–Small Cell Lung Cancer
Case of a Patient With ALK+ Non–Small Cell Lung Cancer
A 58-Year-Old Woman With ALK+ Non–Small Cell Lung Cancer
Lyudmila Bazhenova, MD, presents the case of a 58-year-old woman with ALK+ non–small cell lung cancer.
Moving Beyond JAK Inhibitors in Myeloproliferative Neoplasms
Naveen Pemmaraju, MD, discusses the need to move beyond JAK inhibition when treating patients with myeloproliferative neoplasms.
Phase1b Trial Investigates Atezolizumab and Radium-223 in mCRPC
Michael J. Morris, MD, discusses the safety and clinical activity of atezolizumab plus radium-223 dichloride in patients with second-line metastatic castration-resistant prostate cancer.
Acalabrutinib Shows Promising Results for the Treatment of CLL
Jennifer Woyach, MD, discusses the rationale and efficacy for the phase 1/2 trial of acalabrutinib in patients with chronic lymphocytic leukemia.
KRAS G12C Emerges as New Potential Target in Non-Small Cell Lung Cancer
Edward B. Garon, MD, discusses an exciting new agent, or class of agents, that are under evaluation as treatment of patients with non-small cell lung cancer.
Treating Asymptomatic Patients With Polycythemia Vera
Jerry L. Spivak, MD, discusses treating patients with polycythemia vera, which is a type of myeloproliferative neoplasm that can often derive from essential thrombocythemia, particularly among women.
Case 3: Management of Immune-Related Toxicities in Stage III NSCLC
Case 3: Standard of Care in Unresectable Stage III NSCLC
Case 3: PACIFIC Trial in Unresectable Stage III NSCLC
Case 3: Chemoradiation for Stage III NSCLC
Case 3: Molecular Testing in Stage III NSCLC
Case 3: 63-Year-Old Man With Unresectable Stage IIIA NSCLC
Case 2: Treatment After Progression of EGFR+ NSCLC
Case 2: EGFR+ NSCLC Combination Therapies
Case 2: FLAURA Study for EGFR+ Metastatic NSCLC
Case 2: EGFR-Positive Non–Small Cell Lung Cancer
Case 2: Biomarker Testing for Non–Small Cell Lung Cancer
Case 2: 67-Year-Old Woman With EGFR+ Non–Small Cell Lung Cancer
Case 1: Small Cell Lung Cancer in the Era of Immunotherapy
Case 1: Biomarkers in Small Cell Lung Cancer
Case 1: CASPIAN Trial in Extensive-Stage Small Cell Lung Cancer
Case 1: IMpower133 Trial in Small Cell Lung Cancer
Case 1: Extensive-Stage Small Cell Lung Cancer Background
Case 1: 72-Year-Old Woman With Small Cell Lung Cancer
Clinical Cases in Lung Cancer
Experts in lung oncology review 3 clinical cases and discuss individualized treatment approaches for each patient.
Developing Therapeutic Strategies for Treating Accelerated and Blastic Phase MPN
Srdan Verstovsek, MD, PhD, shares his take home message from his presentation on accelerated and blastic phase myeloproliferative neoplasms during the first Annual Texas MPM Workshop.